Intra-Cellular Therapies Inc. (ITCI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Intra-Cellular Therapies Inc. (ITCI)
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Key Insights
Critical company metrics and information
Share Price
$85.95Market Cap
$9.11 BillionTotal Outstanding Shares
106.02 Million SharesTotal Employees
561Dividend
No dividendIPO Date
December 19, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.intracellulartherapies.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-26.52 Million |
| Net Cash Flow From Financing Activities | $6.73 Million |
| Net Cash Flow From Financing Activities, Continuing | $6.73 Million |
| Net Cash Flow From Investing Activities | $-209.20 Million |
| Net Cash Flow From Operating Activities | $-26.52 Million |
| Net Cash Flow, Continuing | $-228.99 Million |
| Net Cash Flow | $-228.99 Million |
| Net Cash Flow From Investing Activities, Continuing | $-209.20 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Basic Average Shares | $105.77 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Basic Earnings Per Share | $0.25 |
| Income Tax Expense/Benefit | $374000.00 |
| Costs And Expenses | $201.32 Million |
| Operating Income/Loss | $-38.85 Million |
| Research and Development | $66.82 Million |
| Revenues | $175.38 Million |
| Net Income/Loss Attributable To Parent | $-26.32 Million |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Operating Expenses | $214.22 Million |
| Other Operating Expenses | $147.41 Million |
| Income/Loss From Continuing Operations After Tax | $-26.32 Million |
| Diluted Earnings Per Share | $0.25 |
| Benefits Costs and Expenses | $201.32 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Available To Common Stockholders, Basic | $-26.32 Million |
| Diluted Average Shares | $105.77 Million |
| Net Income/Loss | $-26.32 Million |
| Income/Loss From Continuing Operations Before Tax | $-25.95 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $1.27 Billion |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Liabilities | $179.62 Million |
| Noncurrent Assets | $52.71 Million |
| Current Liabilities | $166.11 Million |
| Fixed Assets | $2.00 Million |
| Equity Attributable To Parent | $1.14 Billion |
| Accounts Payable | $10.34 Million |
| Equity | $1.14 Billion |
| Other Non-current Assets | $50.71 Million |
| Assets | $1.32 Billion |
| Noncurrent Liabilities | $13.51 Million |
| Other Current Assets | $1.25 Billion |
| Inventory | $23.54 Million |
| Other Current Liabilities | $155.78 Million |
| Liabilities And Equity | $1.32 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.